Latest News - Genosity Consumer Website

Genosity Enters Into an Agreement With Gemini Therapeutics to Develop a Diagnostic and Implement Testing to Support Gemini’s Age-Related Macular Degeneration Trial

December 16, 2020 08:00 AM Eastern Standard Time

NEW YORK–(BUSINESS WIRE)–Genosity, Inc, a biotechnology company offering novel software and laboratory solutions to enable development and deployment of complex NGS assays, announced an agreement with Gemini Therapeutics to conduct molecular profiling in support of clinical trial patient selection and stratification for Gemini’s GEM103 program in age-related macular degeneration (AMD).

Genosity and Igentify Announce Strategic Collaboration to Integrate Their Offerings, Enabling Comprehensive and Holistic Precision Medicine Solution for Health Systems

November 10, 2020 08:00 AM Eastern Daylight Time

NEW YORK–(BUSINESS WIRE)–Genosity, Inc., an innovative biotechnology company that provides comprehensive software and laboratory solutions to enable precision medicine, announced today that it has entered into a strategic collaboration agreement with Igentify, a digital health technology company that has developed a digital genetic counselor assistant to improve provider interaction with patients for onboarding, enrollment, consenting, as well as facilitating counseling for personalized genetic testing results. Under the terms of agreement, Igentify will integrate its digital platform with Genosity’s Integrated Genomic Toolkit (IGT), and both companies will comarket the combined solution…

19 Organizations from the Healthcare Community Unite to Form COVID-19 Testing Industry Consortium

October 01, 2020 08:00 AM Eastern Daylight Time

Widespread accurate testing for SARS-CoV-2, the virus that causes COVID-19, is one critical aspect needed to limit the spread of the disease. By creating the COVID-19 Testing Industry Consortium, 19 organizations from the healthcare industry have joined forces with a goal to help inform, improve, innovate and accelerate various aspects of testing, ranging from research to clinical diagnostic applications.

The consortium brings together a diverse group of companies with synergistic areas of expertise, including precision medicine, diagnostics, occupational health, pharmaceuticals and clinical testing laboratories, to help provide clarity and potential solutions to COVID-19 testing challenges. To advance the goals of the consortium, members may:

Share relevant expertise, materials and experiences to accelerate understanding of COVID-19.
Analyze available scientific and health data, materials and information to develop, improve and deploy current assays and new approaches for the COVID-19 testing paradigm.
Contribute knowledge gained from the collaborative research by publishing work that will inform the scientific community and general public of the consortium’s findings.
The consortium was organized and is led by Bristol Myers Squibb. Consortium members include:
- Alnylam Pharmaceuticals, Inc.
- ArcherDx, Inc.
- Biocartis NV
- Color
- Diaceutics, PLC
- DxTerity Diagnostics, Inc.
- Genosity, Inc.
- Hematogenix Laboratory Services
- Infinity BiologiX
- Interpace Pharma Solutions, Inc.
- Janssen Pharmaceuticals, NV
- LabCorp
- NeoGenomics Laboratories, Inc.
- Novartis Institute for BioMedical Research
- Ortho-Clinical Diagnostics, Inc.
- Syngene International Limited
- Takeda Pharmaceutical Company Limited (“Takeda”)

“In the three decades devoted to clinical diagnostics, I have been continually amazed that both the complexity and underlying value of testing is been markedly underappreciated. While the unprecedented challenges of the SARS-Covid-2 pandemic have focused a spotlight on the value, there remains a tendency to oversimplify testing. The COVID-19 Testing Consortium has brought together industry expertise to take on the challenge of addressing the details and intricacies that must be resolved if we are to find a holistic solution to both save lives, limit harm and bring life to some semblance of normalcy,” said Marc Grodman M.D. CEO of Genosity Inc. and former Chair of the American Clinical Laboratory Association. “We are proud to be part of a group with the collective knowledge and commitment to make a difference in this time of uncertainty and commend Bristol Myers Squib for their leadership in this effort.”

Genosity and Olink Proteomics Announce Strategic Collaboration

September 29, 2020 08:00 AM Eastern Daylight Time

NEW YORK–(BUSINESS WIRE)–Genosity Inc., and Olink Proteomics AB announced today that they have entered into a strategic services and collaboration agreement within the United States. This will allow Olink to further expand its innovative protein biomarker discovery services for the U.S. market, while enabling Genosity to add high throughput proteomics to its repertoire of available technologies..

Genosity Announces Strategic Software Collaboration with PGDx to Support Distribution of PGDx elio™ Tissue Complete to Laboratories

September 22, 2020 09:00 AM Eastern Daylight Time

NEW YORK–(BUSINESS WIRE)–Genosity, Inc., an innovative biotechnology company that provides comprehensive software and technical solutions to enable precision medicine announced today that it has entered into a strategic collaboration with Personal Genome Diagnostics Inc. (PGDx), one of the leading companies in cancer genomics, that recently received market clearance from the U.S. Food and Drug Administration (FDA) for PGDx elio™ tissue complete, a comprehensive diagnostic kit for genomic profiling of cancer.

Genosity Receives CLIA Approval for AsTra Profile™ and AsTra Next™ to Enable Earlier Detection of Cancer Relapse Through Patient-Specific Liquid Biopsy Monitoring

August 18, 2020 09:00 AM Eastern Daylight Time

NEW YORK–(BUSINESS WIRE)–Genosity Inc., announced today that it has received CLIA approval for its tumor exome and liquid biopsy cancer monitoring platform, AsTra (Assessment and Tracking), designed to identify a patient’s unique tumor molecular profile that can be used for ongoing, personalized Minimal Residual Disease (MRD) monitoring.

Genosity to Investigate Genetics of Cardiac Amyloidosis

Jan 7, 2020

NEW YORK–(BUSINESS WIRE)–Genosity Inc. announced today that it has partnered with Columbia University Irving Medical Center to investigate genetic factors associated with wild-type cardiac amyloidosis, a type of heart failure caused by the buildup of amyloid protein.

Next Generation Dx Summit

Aug 20-22 2019, Washington, DC

Interested in learning about new data strategies and solutions available to clinical laboratories? Stop by for a Breakfast Discussion on Thursday, August 22nd, 7:30AM to hear Genosity’s President and CTO, Robert D. Daber, PhD, DABMG as he explores:

The changing landscape, challenges, and trends in laboratory data management
How to bridge the gap between molecular and clinical data
How to implement an informatics infrastructure for data curation, clinical validation, and quality reporting

ArcherDX Announces Broad-Based Strategic Collaboration with Genosity

Feb 12 2019

BOULDER, Colo., Feb. 12, 2019 /PRNewswire/ — ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.

AMP 2018 Annual Meeting

Nov 1-3 2018, San Antonio, TX

Genosity will be exhibiting at the AMP annual meeting. Stop by our booth 1408 to find out about our new exciting products.

Bio-IT World Conference and Expo

May 15-17, 2018

Genosity will be exhibiting at the Bio-IT meeting. Stop by our booth 308 to meet us and learn what we have to offer.